|
|
Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa |
 Schering-Plough Corp., (NYSE: SGP) has announced results from the Phase III ENGAGE clinical trial demonstrating that a single injection of corifollitropin alfa, first in the class of sustained follicle stimulants, achieved similar efficacy to recombinant follicle stimulating hormone (rFSH) given once daily for seven days. |
|
|
|
|
Tuesday, 15 September 2009 |
 |
 |
 |
|
|
Global Study Provides Additional Information About an Intensified Dose-Regimen of Plavix® |
 The OASIS study group has presented initial results of the CURRENT-OASIS 7 clinical trial at the European Society of Cardiology congress in Barcelona. Sanofi-aventis (EURONEXT: SAN, and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY), co-commercialization and co-development partners for PLAVIX® (clopidogrel bisulfate), were sponsors of the study.
|
|
|
|
Wednesday, 18 November 2009 |
|
|
|
|
|
Study Meets Primary Endpoint with 25 Percent LDL Reduction in Very High-Risk Patient Population |
 Genzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) presented the data from the phase 3 study of mipomersen in patients with homozygous familial hypercholesterolemia (hoFH). The study met its primary endpoint in an intent-to-treat analysis, with a 25 percent reduction in LDL-cholesterol after 26 weeks of treatment, vs. 3 percent for placebo (p<0.001) which constitutes an average reduction greater than 100 mg/dL. The trial also met each of its secondary endpoints.
|
|
|
|
|
Wednesday, 21 October 2009 |
|
|
|
|
|
Diabetes Conversation Map(TM) Education Tools Celebrate One-Year Anniversary |
 This October marks the one-year anniversary of the international launchof the ground-breaking diabetes Conversation Map(TM) education tools. Created by Healthy Interactions, a global leader in health education, in collaboration with the International Diabetes Federation (IDF), Eli Lilly and Company and other leading diabetes experts, the unique Conversation Map(TM) education tools have been implemented in 68 countries, excluding the United States, in 31 different languages in the last 365 days. |
|
|
|
Wednesday, 25 November 2009 |
|
|
|
|
|
Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa |
 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, has submitted a MAA to the European Medicines Agency for velaglucerase alfa, the company's enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease. This is the third marketing application for velaglucerase alfa that has been submitted, with previous submissions in the United States and Canada.
|
|
|
|
|
|
|
|
|
Page 1 of 94 |
